000			06296cam a2200709Ii 4500
005			20250919140359.0
006			m o d
007			cr cnu|||unuuu
008			190918s2017 gw a ob 001 0 eng d
020			_a9783527805938 _q(electronic bk.)
020			_a3527805931 _q(electronic bk.)
020			_a9783527805921 _q(electronic bk.)
020			_a3527805923 _q(electronic bk.)
020			_z9783527342051
020			_z3527342052
035			_a(OCoLC)1002418559 _z(OCoLC)1002830648
035			_a(OCoLC)on1002418559
039		9	_a201911041147 _bros _y09-18-2019 _zhafiz _wUKM UBCM Wiley MARC (363 titles).mrc _x318
040			_aNST _beng _erda _epn _cNST _dIDEBK _dEBLCP _dNLE _dNST _dDG1 _dOCLCF _dRECBK _dMERER _dYDX _dUAB
049			_aMAIN
050		4	_aQP601
072		7	_aMED _x075000 _2bisacsh
072		7	_aSCI _x036000 _2bisacsh
082	0	4	_a612.0151 _223
245	0	0	_aNatural products targeting clinically relevant enzymes / _cedited by Paula B. Andrade, Patr{u2A63}ia Valent, David M. Pereira.
264		1	_aWeinheim, Germany : _bWiley-VCH, _c[2017]
264		4	_cò017
300			_a1 online resource : _billustrations
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
504			_aIncludes bibliographical references.
505	8		_a2.3 Proteasome Inhibitors2.3.1 Carmaphycins; 2.4 Protease Enzymes; 2.4.1 Serine Protease Inhibitors; 2.4.2 Falcipain Inhibitors; 2.4.2.1 Gallinamide A; 2.4.3 Cathepsin Inhibitors; 2.4.4 b-Secretase 1 (BACE1) Inhibitors; 2.4.4.1 Tasiamide B; 2.5 Protein Kinase C Modulators; 2.5.1 Aplysiatoxins; 2.6 Interference of the Actin and Microtubule Filaments; 2.6.1 Dolastatins 10/15; 2.6.2 Bisebromoamide; 2.7 Sec61 Protein Translocation Channel Inhibitors; 2.7.1 Apratoxin A; 2.8 Prohibitin Inhibitors; 2.8.1 Aurilide; 2.9 Sodium Channels Modulators; 2.10 Conclusions; References
505	8		_a4.3 Marine Molecules as PLA2 Inhibitors4.3.1 Sponge-Derived Metabolites; 4.3.2 Metabolites from Other Organisms; 4.4 Conclusion; References; Chapter 5 b-Secretase (BACE1) Inhibitors from Natural Products; 5.1 Introduction; 5.2 Flavonoids; 5.2.1 Flavones, Flavonols and Flavone Glycosides; 5.2.2 Dihydroflavonoids; 5.2.3 Biflavonoids; 5.2.4 Chalcones; 5.2.5 Isoflavonoids; 5.2.6 Catechins; 5.2.7 Xanthones; 5.3 Chromones; 5.4 Phenolic Acids and Tannins; 5.4.1 Phenol Acids; 5.4.2 Tannins; 5.4.3 Simple Phenol Derivatives and Polyphenols; 5.5 Stilbenes and Derivatives; 5.6 Coumarins
505	8		_a5.7 Benzoquinones and Anthraquinones5.8 Alkaloids; 5.9 Terpenes; 5.10 Lignans; 5.11 Fatty Acid; 5.12 Saccharides, Peptides and Amino Acid Derivatives; 5.13 BACE1 Inhibitory Active Extracts of Natural Products; 5.14 Bioassays for the Discovery of BACE1 Inhibitors; 5.15 Prospective; Acknowledgements; References; Chapter 6 Hypoglycaemic Effects of Plants Food Constituents via Inhibition of Carbohydrate-Hydrolysing Enzymes: From Chemistry to Future Applications; 6.1 Introduction; 6.2 a-Amylase; 6.3 a-Glucosidase; 6.4 Hypoglycaemic Natural Compounds; 6.4.1 Flavonoids; 6.4.2 Phenolic Acids
505	0		_aCover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Natural Products as Enzyme Inhibitors; 1.1 Why Are Natural Products Good Enzyme Inhibitors?; 1.2 Drawbacks of Natural Products; 1.3 The Future of Natural Products Drug Discovery; 1.3.1 New Sources and New Production Methods; 1.3.2 New Strategies for Delivery; 1.3.3 New Targets?/Drug Repurposing; 1.4 Conclusion; References; Chapter 2 Molecular Targets of Clinically Relevant Natural Products from Filamentous Marine Cyanobacteria; 2.1 Introduction; 2.2 Histone Deacetylase Inhibitors; 2.2.1 Largazole; 2.2.2 Santacruzamate A
505	8		_aChapter 3 Natural Angiotensin Converting Enzyme (ACE) Inhibitors with Antihypertensive Properties3.1 Introduction; 3.2 Mechanisms of Blood Pressure Regulation; 3.2.1 Renin-Angiotensin-Aldosterone System; 3.3 The Treatment of Hypertension; 3.3.1 Angiotensin Converting Enzyme Inhibitors; 3.4 Natural Products as Angiotensin Converting Enzyme Inhibitors; 3.4.1 Polyphenols; 3.4.2 Protein Derived Peptides; 3.5 Conclusions; References; Chapter 4 Phospholipase A2 Inhibitors of Marine Origin; 4.1 Relevance of Marine Organisms; 4.2 Inflammation; 4.2.1 Phospholipase A2
520			_aThe past decade has seen the reappearance of natural products as a valuable source of potent therapeutics. Here, experts on bioactive natural products cover the full spectrum of clinically relevant enzymes that are known to be targeted by natural products. Key enzymes include acetylcholine esterase, angiotensin-I-converting enzyme, cyclooxygenase, dihydrofolate reductase, phospholipase A2, respiratory complexes, and many more. By connecting the diversity of medicinal natural product sources with their potential clinical applications, this volume serves as a companion for the medicinal chemist looking for innovative small molecule compounds as well as for pharmacologist interested in the clinical effects and mode of action of herbal and traditional medicines.
588	0		_aOnline resource; title from PDF title page (EBSCO, viewed September 11, 2017).
650		0	_aEnzymes _xEffect of drugs on.
650		0	_aNatural products _xTherapeutic use.
650		0	_aBioactive compounds.
650		7	_aMEDICAL / Physiology. _2bisacsh
650		7	_aSCIENCE / Life Sciences / Human Anatomy & Physiology. _2bisacsh
650		7	_aBioactive compounds. _2fast _0(OCoLC)fst00831933
650		7	_aEnzymes _xEffect of drugs on. _2fast _0(OCoLC)fst00913612
650		7	_aNatural products _xTherapeutic use. _2fast _0(OCoLC)fst01034400
655		4	_aElectronic books.
655		0	_aElectronic books.
700	1		_aAndrade, Paula B., _eeditor.
700	1		_aValentao, Patricia, _eeditor.
700	1		_aPereira, David M., _eeditor.
773	0		_tWiley e-books
776	0	8	_cOriginal _z9783527342051 _z3527342052 _w(OCoLC)989967773
856	4	0	_uhttps://eresourcesptsl.ukm.remotexs.co/user/login?url=https://doi.org/10.1002/9783527805921 _zWiley Online Library
907			_a.b1675816x _b2022-11-08 _c2019-11-12
942			_n0
914			_avtls003651473
998			_ae _b2019-05-09 _cm _dz _feng _ggw _y0 _z.b1675816x
999			_c643703 _d643703